Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: A nested analysis within the Costa Rica Vaccine Trial

Journal of Infectious Diseases

Volumn 210, Issue 12, 2014, Pages 1890-1899

  Kuhs, Krystle A Lang ^a   Gonzalez, Paula ^b,c   Rodriguez, Ana Cecilia ^b   Van Doorn, Leen Jan ^d   Schiffman, Mark ^a   Struijk, Linda ^d   Chen, Sabrina ^e   Quint, Wim ^d   Lowy, Douglas R ^a   Porras, Carolina ^b   Delvecchio, Corey ^e   Jimenez, Silvia ^b   Safaeian, Mahboobeh ^a   Schiller, John T ^a   Wacholder, Sholom ^a   Herrero, Rolando ^b,c   Hildesheim, Allan ^a   Kreimer, Aimée R ^a   Alfaro, Mario ^b   Barrantes, Manuel ^b   Concepcion Bratti M ^b   Cárdenas, Fernando ^b   Cortés, Bernal ^b   Espinoza, Albert ^b   Estrada, Yenory ^b   Guillén, Diego ^b   Jiménez, Silvia E ^b   Morales, Jorge ^b   Villegas, Luis ^b   Morera, Lidia Ana ^b   Pérez, Elmer ^b   Rivas, Libia ^b   Freer, Enrique ^f   Bonilla, José ^f   García Piñeres, Alfanso ^f   Silva, Sandra ^f   Atmella, Ivannia ^f   Ramírez, Margarita ^f   Macklin, Nora ^a   Sherman, Mark ^a   Solomon, Diane ^a   Pinto, Ligia ^g   Kemp, Troy ^g   Eklund, Claire ^h   Hutchinson, Martha ^h   Sidawy, Mary ⁱ   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d Manager Development and Diagnostic Services (DDS)   (Netherlands)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

^f UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^g SAIC FREDERICK INC   (United States)

^h WOMEN AND INFANTS HOSPITAL   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

Author keywords

Costa Rica; HPV; HPV vaccine; Vulvar human papillomavirus vaccine

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; COSTA RICA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; VACCINATION; VIRUS DETECTION; ADOLESCENT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVIX; VIROLOGY; VULVA; VULVAR DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; CERVIX UTERI; COSTA RICA; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; VULVA; VULVAR DISEASES; YOUNG ADULT;

EID: 84923790923     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu357     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997;90:448-52.
3. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
4. Sturgeon SR, Brinton LA, Devesa SS, Kurman RJ. In situ and invasive vulvar cancer incidence trends (1973 to 1987). Am J Obstet Gynecol 1992;166:1482-5.
5. Iversen T, Tretli S. Intraepithelial and invasive squamous cell neoplasia of the vulva: trends in incidence, recurrence, and survival rate in Norway. Obstet Gynecol 1998;91:969-72.
6. Messing MJ, Gallup DG. Carcinoma of the vulva in young women. Obstet Gynecol 1995;86:51-4.
7. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(suppl 5):F12-23.
8. Arbyn M, de Sanjose S, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012;131:1969-82.
9. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
11. Garland SM. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against vulvar/vaginal intraepithelial neoplasia. In: IPV Conference, Berlin, 2011.
12. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Koutsky LA. Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis 2009;199:815-8.
13. Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev 2009;18:1777-84.
14. Abalos AT, Harris RB, Nyitray AG, et al. Human papillomavirus type distribution among heterosexual couples. J Low Genit Tract Dis 2012;16:10-5.
15. Barzon L, Militello V, Pagni S, et al. Distribution of human papillomavirus types in the anogenital tract of females and males. J Med Virol 2010;82:1424-30.
16. Rumbold AR, Tan SE, Condon JR, et al. Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence. BMC Infect Dis 2012;12:243.
17. Howell-Jones R, de Silva N, Akpan M, et al. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 2012;30:3867-75.
18. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-808.
19. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12:862-70.
20. Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a communitybased randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011;1:408-19.
21. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-9.
22. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
23. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006;44:3292-8.
24. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLOS One 2013;8:e68329.
25. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. new ed. Boston, MA, USA: Epidemiology Resources Inc, 1982.
26. Agresti A. Categorical data analysis. 2nd ed. Hoboken, NJ: John Wiley and Sons Inc., 2002.
27. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
28. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99.
29. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.